Reduction of Microembolism After the Intervention Surgery of Intracranial Aneurysms by Administration of Tirofiban

• Status: Recruiting
• Trial end date: 2023-08-31
• Target enrollment: 0
• Participant gender: All

Summary

The goal of this clinical trial is to investigate whether intravenous injection of tilofiban can reduce microembolism in patients with unruptured intracranial aneurysms after Stent-Assisted Coil Embolization.The main questions it aims to answer are:

• Is it safe to inject tirofiban intravenously during interventional treatment of intracranial aneurysms？

• What dose of tirofiban is safe and effective?

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Lu Hua
• Treatments: Tirofiban

Criteria

Inclusion Criteria:

• Age was between 18 and 75 years old;

• Unruptured aneurysm with surgical indications;

• Stent assisted coil embolization treatment was received ;

• The patient was willing to receive intervention treatment.

Exclusion Criteria:

• Complicated with hemorrhagic cerebrovascular diseases such as cerebral vascular malformations and moyamoya disease or their medical history;

• Recent (within 1 year) bleeding symptoms such as gastrointestinal bleeding, clinically significant urinary/reproductive tract bleeding, and skin blueness;

• Dissecting aneurysm, pseudoaneurysm, and bullous aneurysm;

• A known history of coagulation disorders, platelet abnormalities, or thrombocytopenia;

5. Platelet count less than 150 × 109/L；

• A history of major surgical procedures or severe physical trauma within one month;

• Severe uncontrolled hypertension (systolic blood pressure>160mmHg and/or diastolic blood pressure>100mmHg);

• Hemorrhagic retinopathy;

• Chronic hemodialysis;

• Renal insufficiency.